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DES May Impair Collateral Formation
Meier and colleagues hypothesized that because drug-eluting stents (DES) delayhealing of the endothelium, they may also delay the formation of collateral
circulation that is normally stimulated by cytokines and growth factors released from
the endothelium.A total of 120 patientswhohad received either aDESor a bare-metal
stent were matched for the severity of in-stent restenosis and the time since stent
implantation.The collateral flow index (CFI)was calculated bymeasuring the pressure
in the vessel distal to the stent during balloon inflation inside the stent. The CFI was
diminished in the DES group and patients with DES were more likely to have
ST-segment elevation during balloon occlusion. This study suggests that DES may
impair collateral formation up to 6 months after stent implantation. See page 15.
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Heart Failure
Isosorbide Dinitrate/Hydralazine Safe With Low SBP
Studies have shown that low systolic blood pressure (SBP) is a negative prognosticindicator in patients with congestive heart failure, and there is reluctance to start
vasodilatory medications in patients with low blood pressure (BP) for fear of causing
orthostasis. Anand and colleagues examined the role of SBP in the A-HeFT study.
Although mortality was 2 times higher when the initial SBP was below the median of
126mmHg, the benefits of isosrbide dinitrate/hydralazine were apparent regardless of
the starting BP. Whereas patients with low initial SBP were more likely to report
dizziness with isosrbide dinitrate/hydralazine than with placebo, the discontinuation
rates for low BP symptoms were not different. This study suggests that patients with
systolic dysfunction and low BP can still benefit from vasodilator therapy.See pages
32 and 40. See figure.
Heart Rhythm Disorders
Microvolt T-Wave Alternans Identifies Patients Who Benefit From ICD Therapy
Chowand colleagues collected the results ofmicrovolt T-wave alternans (MTWA)testing from over 700 patients with ischemic cardiomyopathy (left ventricular
ejection fraction35%).One-half of these patients received implantable cardioverter-
defibrillators (ICDs), but this was not randomized or dependent on the results of
MTWA testing. For the two-thirds of patients who tested non-negative for MTWA,
ICD implantation reduced the subsequent risk of death by over 50%. There was no
benefit in those who tested negative. The number needed to treat with an ICD to save
one life was 9 amongMTWA-non-negative patients and 76 amongMTWA-negative
patients, suggesting that MTWA may be a useful method for determining which
patients with ischemic cardiomyopathies should undergo ICD implantation. See
pages 50 and 59.
(continued) A-34Thyroid Heart Disease
Cardiovascular Effects of Hyperthyroidism Continue After Treatment
Although it is generally recognized that hyperthyroidism can cause transient car-diovascular effects, little is known about the prevalence of these symptoms or
whether these symptoms resolve as patients return to a euthyroid state. Osman and
colleagues collected detailed information about cardiac symptoms in almost 400
patients with hyperthyroidism and compared them to a matched cohort. The same
evaluations were then repeated as the thyroid abnormalities were treated. Patients with
hyperthyroidism were much more likely to report symptoms of palpitations and
dyspnea and approximately 8% had evidence of atrial fibrillation; they were also more
likely tohave a fall in systolic bloodpressureupon standing.Thesedifferences remained
even after patients were restored to a euthyroid state. Cardiovascular abnormalities are
common in patients with overt hyperthyroidism at presentation, but some abnormal-
ities persist despite effective antithyroid therapy. See page 71.
